A novel coronavirus (SARS-CoV-2) originated from the Human Seafood Market in Wuhan, China. World Health Organization named it as COVID-19 which spread quickly all over the country and the world. The sources and the pathogenesis characteristics of this virus are still unidentified. In the meantime, many independent researcher groups have identified that the SARS-CoV-2 belongs to β-coronavirus with identical genome sequence to bat coronavirus, and pointing out that bat is the natural host. The COVID-19 utilizes the similar receptor angiotensin converting enzyme-2 (ACE-2) as like SARS-CoV and commonly spreads via the respiratory tract infection. The clinical sign and symptoms of COVID-19 include cough, fever, fatigue, headache and breathing problem. The elderly patients and people with underlying disorders are more susceptible to infection and prone to serious effects which may be associated with some of the acute respiratory distress syndrome. There is no specific treatment such as vaccination and therapeutic drug molecule has not been found. Currently, some antiviral drugs are in used for the treatment of coronavirus but they are not that much effective. In this review article, we focus on the general overview and pathogenesis characteristics of COVID-19. In this we have discussed the various vaccination strategies, use of traditional medicine system and convalescent plasma therapy for the treatment of coronavirus. Also we highlight the break chain theory which helps to avoid the transmission of virus from one human body to another. The worldwide impact of this epidemic is still undetermined. 

2. WHO. Novel coronavirus. WHO. p. 2020; 2019–. nCoV) situation report - 1 (website) [cited Jan 212020]. Available from: https://www.who.int/docs/default-source/coronavirus/situation-reports/20200121-sitrep-1-2019-ncov.pdf?sfvrsn¼20a99c10_4.

3. WHO. Novel coronavirus. WHO. p. 2020; 2019–. nCoV) situation report - 11 (website) [cited Jan 312020]. Available from: mailto. Available from: https://www.who.int/docs/default-source/coronaviruse/situationreports/20200131-sitrep-11-ncov.pdf? sfvrsn¼de7c0f7_4.

4. WHO. Coronavirus disease (COVID-2019) situation reports; 2020. https: [citedMar52020]. Available from: mailto. Available from: http://www.who.int/emergencies/diseases/novel-coronavirus2019/situationreports.

5. Lee A. Wuhan novel coronavirus (COVID-19): why global control is challenging? Public Health. 2020;179:A1-2. doi: 10.1016/j.puhe.2020.02.001, PMID 32111295.

6. Malik YS, Sircar S, Bhat S, Vinodhkumar OR, Tiwari R, Sah R, Dhama K. Emerging coronavirus Disease (COVID-19), a pandemic public health emergency with animal linkages: current status update; 2020.

7. Shen Z, Ning F, Zhou W, He X, Lin C, Chin DP, Zhu Z, Schuchat A. Superspreading SARS events, Beijing, 2003. Emerg Infect Dis. 2004;10(2):256-60. doi: 10.3201/eid1002.030732, PMID 15030693.

8. Kucharski AJ, Althaus CL. The role of superspreading in Middle East respiratory syndrome coronavirus (MERS-CoV) transmission. Euro Surveill. 2015;20(25):14-8. doi: 10.2807/1560-7917.es2015.20.25.21167, PMID 26132768.

9. Riou J, Althaus CL. Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020. EURO Surveill. 2020;25(4). doi: 10.2807/1560-7917.ES.2020.25.4.2000058, PMID 32019669.

10. Liu Y, Gayle AA, Wilder-Smith A, Rocklöv J. The reproductive number of COVID-19 is higher compared to SARS coronavirus. J Travel Med. 2020;27(2):1-4. doi: 10.1093/jtm/taaa021, PMID 32052846.

11. St John RK, King A, De Jong D, Bodie-Collins M, Squires SG, Tam TW. Border screening for SARS. Emerg Infect Dis. 2005;11(1):6-10. doi: 10.3201/eid1101.040835, PMID 15705315.

12. Selvey LA, Antão C, Hall R. Entry screening for infectious diseases in humans. Emerg Infect Dis. 2015;21(2):197-201. doi: 10.3201/eid2102.131610, PMID 25625224.

13. Olsen SJ, Chang HL, Cheung TYY, Tang AFY, Fisk TL, Ooi SPL, Kuo HW, Jiang DD, Chen KT, Lando J, Hsu KH, Chen TJ, Dowell SF. Transmission of the severe acute respiratory syndrome on aircraft. Med. 2003;349(25):2416-22. doi: 10.1056/NEJMoa031349, PMID 14681507.

14. Naina JA. Need to break chain of transmission of coronavirus [citedMar202020]. Available from: https://www.deccanherald.com/state/mangaluru/need-to-break-chain-of-transmission-of-coronavirus-815918.html.

15. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17(3):181-92. doi: 10.1038/s41579-018-0118-9, PMID 30531947.

16. Wong ACP, Li X, Lau SKP, Woo PCY. Global epidemiology of bat coronaviruses. Viruses. 2019;11(2):174. doi: 10.3390/v11020174, PMID 30791586.

17. Li W, Sui J, Huang IC, Kuhn JH, Radoshitzky SR, Marasco WA, Choe H, Farzan M. The S proteins of human coronavirus NL63 and severe acute respiratory syndrome coronavirus bind overlapping regions of ACE2. Virology. 2007;367(2):367-74. doi: 10.1016/j.virol.2007.04.035, PMID 17631932.

18. Hulswit RJG, Lang Y, Bakkers MJG, Li W, Li Z, Schouten A, Ophorst B, van Kuppeveld FJM, Boons GJ, Bosch BJ, Huizinga EG, de Groot RJ. Human coronaviruses OC43 and HKU1 bind to 9-O-acetylated sialic acids via a conserved receptor-binding site in spike protein domain A. Proc Natl Acad Sci U S A. 2019;116(7):2681-90. doi: 10.1073/pnas.1809667116, PMID 30679277.

19. Middle East respiratory syndrome coronavirus [citedFeb162020]. Available from: https://www.who.int/emergencies/mers-cov/en/.

20. Lian J, Jin X, Hao S, Cai H, Zhang S, Zheng L, Jia H, Hu J, Gao J, Zhang Y, Zhang X, Yu G, Wang X, Gu J, Ye C, Jin C, Lu Y, Yu X, Yu X, Ren Y, Qiu Y, Li L, Sheng J, Yang Y. Analysis of epidemiological and clinical features in older patients with coronavirus disease 2019 (COVID-19) outside Wuhan. Clin Infect Dis. 2020;71(15):740-7. doi: 10.1093/cid/ciaa242, PMID 32211844.

21. Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, Zhong W, Hao P. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci. 2020;63(3):457-60. doi: 10.1007/s11427-020-1637-5, PMID 32009228.

22. Knoops K, Kikkert M, Worm SH, Zevenhoven-Dobbe JC, van der Meer Y, Koster AJ, Mommaas AM, Snijder EJ. SARS-coronavirus replication is supported by a reticulo vesicular network of modified endoplasmic reticulum. PLOS Biol. 2008;6(9):e226. doi: 10.1371/journal.pbio.0060226, PMID 18798692.

23. Cheng ZJ, Shan J. 2019 Novel coronavirus: where we are and what we know. Infection. 2020;48(2):155-63. doi: 10.1007/s15010-020-01401-y, PMID 32072569.

24. Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP, Fang C, Huang D, Huang LQ, Huang Q, Han Y, Hu B, Hu F, Li BH, Li YR, Liang K, Lin LK, Luo LS, Ma J, Ma LL, Peng ZY, Pan YB, Pan ZY, Ren XQ, Sun HM, Wang Y, Wang YY, Weng H, Wei CJ, Wu DF, Xia J, Xiong Y, Xu HB, Yao XM, Yuan YF, Ye TS, Zhang XC, Zhang YW, Zhang YG, Zhang HM, Zhao Y, Zhao MJ, Zi H, Zeng XT, Wang YY, Wang XH, , for the Zhongnan Hospital of Wuhan University Novel Coronavirus Management and Research Team, Evidence-Based Medicine Chapter of China International Exchange and Promotive Association for Medical and Health Care (CPAM), for the Zhongnan Hospital of Wuhan University Novel Coronavirus Management and Research Team. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res. 2020;7(1):4. doi: 10.1186/s40779-020-0233-6, PMID 32029004.

25. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, Xing X, Xiang N, Wu Y, Li C, Chen Q, Li D, Liu T, Zhao J, Liu M, Tu W, Chen C, Jin L, Yang R, Wang Q, Zhou S, Wang R, Liu H, Luo Y, Liu Y, Shao G, Li H, Tao Z, Yang Y, Deng Z, Liu B, Ma Z, Zhang Y, Shi G, Lam TTY, Wu JT, Gao GF, Cowling BJ, Yang B, Leung GM, Feng Z. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382(13):1199-207. doi: 10.1056/NEJMoa2001316, PMID 31995857.

26. Lee PI, Hsueh PR. Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV. J Microbiol Immunol Infect. 2020;53(3):365-7. doi: 10.1016/j.jmii.2020.02.001, PMID 32035811.

27. Zhang W, Du RH, Li B, Zheng XS, Yang XL, Hu B, Wang YY, Xiao GF, Yan B, Shi ZL, Zhou P. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect. 2020;9(1):386-9. doi: 10.1080/22221751.2020.1729071, PMID 32065057.

28. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-13. doi: 10.1016/S0140-6736(20)30211-7, PMID 32007143.

29. Poutanen SM, Low DE, Henry B, Finkelstein S, Rose D, Green K, Tellier R, Draker R, Adachi D, Ayers M, Chan AK, Skowronski DM, Salit I, Simor AE, Slutsky AS, Doyle PW, Krajden M, Petric M, Brunham RC, McGeer AJ, National Microbiology Laboratory, Canadian Severe Acute Respiratory Syndrome Study Team. Identification of severe acute respiratory syndrome in Canada. Med. 2003;348(20):1995-2005. doi: 10.1056/NEJMoa030634, PMID 12671061.

30. Cao M, Zhang D, Wang Y, Lu Y, Zhu X, Li Y, Xue H, Lin Y, Zhang M, Sun Y, Yang Z, Shi J, Wang Y, Zhou C, Dong Y, Liu P, Dudek SM, Xiao Z, Lu H, Peng L. Clinical features of patients infected with the 2019 novel coronavirus (COVID-19) in Shanghai, China. MedRxiv. 2020. doi: 10.1101/2020.03.04.20030395, PMID 32511465.

31. Global Network Report. Available online [citedFeb192020]. Available from: https://baijiahao.baidu.com/s?id=1656696048015939580&wfr=spider&for=pc.

32. Charlton CL, Babady E, Ginocchio CC, Hatchette TF, Jerris RC, Li Y, Loeffelholz M, McCarter YS, Miller MB, Novak-Weekley S, Schuetz AN, Tang YW, Widen R, Drews SJ. Practical guidance for clinical microbiology laboratories: viruses causing acute respiratory tract infections. Clin Microbiol Rev. 2019;32(1). doi: 10.1128/CMR.00042-18, PMID 30541871.

33. Cheng PK, Wong DA, Tong LK, Ip SM, Lo AC, Lau CS, Yeung EY, Lim WW. Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome. Lancet. 2004;363(9422):1699-700. doi: 10.1016/S0140-6736(04)16255-7, PMID 15158632.

34. Sun D, Li H, Lu XX, Xiao H, Ren J, Zhang FR, Liu ZS. Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center’s observational study. World J Pediatr. 2020;16(3):251-9. doi: 10.1007/s12519-020-00354-4, PMID 32193831.

35. Centers for Disease control and Prevention. Interim laboratory biosafety guidelines for handling and processing specimens associated with coronavirus Disease 2019 (COVID-19)[citedMar212020]. Available from: https://www.cdc.gov/coronavirus/2019-nCoV/lab/lab-biosafety-guidelines.html.

36. Centers for Disease Control and Prevention, CDC. Novel coronavirus (2019-nCoV) real-time RT-PCR Diagnostic Panel.  [citedMar152020]; 2019–. Available from: https://www.fda.gov/media/134922/download.

37. Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknownetiology in Wuhan, China: themystery and the miracle. J Med Virol. 2020;92(4):401-2. doi: 10.1002/jmv.25678, PMID 31950516.

38. Kim Y, Liu H, Galasiti Kankanamalage AC, Weerasekara S, Hua DH, Groutas WC, Chang KO, Pedersen NC. Reversal of the progression of fatal coronavirus infection in cats by a broad-spectrum coronavirus protease inhibitor. PLOS Pathog. 2016;12(3):e1005531. doi: 10.1371/journal.ppat.1005531, PMID 27027316.

39. Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses—drug discovery and therapeutic options. Nat Rev Drug Discov. 2016;15(5):327-47. doi: 10.1038/nrd.2015.37, PMID 26868298.

40. Chu CM, Cheng VCC, Hung IFN, Wong MML, Chan KH, Chan KS, Kao RY, Poon LL, Wong CL, Guan Y, Peiris JS, Yuen KY, HKU/UCH SARS Study Group. Role of lopinavir/ritonavir in the treatment of SARS: initialvirological and clinical findings. Thorax. 2004;59(3):252-6. doi: 10.1136/thorax.2003.012658, PMID 14985565.

41. Arabi YM, Alothman A, Balkhy HH, Al-Dawood A, AlJohani S, Al Harbi S, Kojan S, Al Jeraisy M, Deeb AM, Assiri AM, Al-Hameed F, AlSaedi A, Mandourah Y, Almekhlafi GA, Sherbeeni NM, Elzein FE, Memon J, Taha Y, Almotairi A, Maghrabi KA, Qushmaq I, Al Bshabshe A, Kharaba A, Shalhoub S, Jose J, Fowler RA, Hayden FG, Hussein MA, And the MIRACLE trial group. Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial. Trials. 2018;19(1):81. doi: 10.1186/s13063-017-2427-0. PMID 29382391.

42. Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, Montgomery SA, Hogg A, Babusis D, Clarke MO, Spahn JE, Bauer L, Sellers S, Porter D, Feng JY, Cihlar T, Jordan R, Denison MR, Baric RS. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11(1):222. doi: 10.1038/s41467-019-13940-6, PMID 31924756.

43. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect Dis. 2003;3(11):722-7. doi: 10.1016/s1473-3099(03)00806-5, PMID 14592603.

44. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, Seidah NG, Nichol ST. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2(1):69. doi: 10.1186/1743-422X-2-69, PMID 16115318.

45. Munster VJ, Koopmans M, van Doremalen N, van Riel D, de Wit E. A Novel Coronavirus Emerging in China - Key Questions for Impact Assessment. Med. 2020;382(8):692-4. doi: 10.1056/NEJMp2000929, PMID 31978293.

46. Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, Wang J, Qin Y, Zhang X, Yan X, Zeng X, Zhang S. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the Perspectives of clinical immunologists from China. Clin Immunol. 2020;214:108393. doi: 10.1016/j.clim.2020.108393.

47. Singh IS, Hasday JD. Fever, hyperthermia and the heat shock response. Int J Hyperthermia. 2013;29(5):423-35. doi: 10.3109/02656736.2013.808766, PMID 23863046.

48. Zeng QL, Yu ZJ, Gou JJ, Li GM, Ma SH, Zhang GF, Xu JH, Lin WB, Cui GL, Zhang MM, Li C, Wang ZS, Zhang ZH, Liu ZS. Effect of convalescent plasma therapy on viral shedding and survival in patients with coronavirus disease 2019. J Infect Dis. 2020;222(1):38-43. doi: 10.1093/infdis/jiaa228, PMID 32348485.

49. Lindholm PF, Ramsey G, Kwaan HC. Passive immunity for coronavirus disease 2019: a commentary on therapeutic aspects including convalescent plasma. Semin Thromb Hemost. 2020;46(7):796-803. doi: 10.1055/s-0040-1712157, PMID 32526774.

50. Vartak A, Sucheck SJ. Recent advances in subunit vaccine carriers. Vaccines. 2016;4(2):12. doi: 10.3390/vaccines4020012, PMID 27104575.

51. Liu MA. DNA vaccines: an historical perspective and view to the future. Immunol Rev. 2011;239(1):62-84. doi: 10.1111/j.1600-065X.2010.00980.x, PMID 21198665.

52. Choi J, Kim MG, Oh YK, Kim YB. Progress of Middle East respiratory syndrome coronavirus vaccines: a patent review. Expert Opin Ther Pat. 2017;27(6):721-31. doi: 10.1080/13543776.2017.1281248, PMID 28121202.

53. Badgujar KC, Badgujar VC, Badgujar SB. Vaccine development against coronavirus (2003 to present): an overview, recent advances, current scenario, opportunities and challenges. Diabetes Metab Syndr Clin Res Rev. 2020;14(5):1361-76. doi: 10.1016/j.dsx.2020.07.022, PMID 32755836.

54. Mohan P, Singhal A, Mangal M. Novel coronavirus vaccine: an international holy grail. J Mar Med Soc. 2020. doi: 10.4103/jmms.jmms_92_20.

55. US National Library of Medicine. Clinical. Trials.gov,  BCG Vaccination to protect Health care workers against COVID-19 (BRACE) NCT04327206.

56. US National Library of Medicine. Clinical. Trials.gov,  Reducing Health care Workers Absenteeism in Covid -19 Pandemic  Through BCG Vaccine (BCG – CORONA).

57. Van Doremalen N, Lambe T, Spencer A, Belij-Rammerstorfer S, Purushotham JN, Port JR, Avanzato V, Bushmaker T, Flaxman A, Ulaszewska M, Feldmann F. ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques. bioRxiv. 2020.05.13.093195:2020. doi: 10.1101/2020.05.13.093195.

58. Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, Wu SP, Wang BS, Wang Z, Wang L, Jia SY, Jiang HD, Wang L, Jiang T, Hu Y, Gou JB, Xu SB, Xu JJ, Wang XW, Wang W, Chen W. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395(10240):1845-54. doi: 10.1016/S0140-6736(20)31208-3, PMID 32450106.

59. Corbett KS, Edwards D, Leist SR, Abiona OM, Boyoglu-Barnum S, Gillespie RA, Himansu S, Schäfer A, Ziwawo CT, DiPiazza AT, Dinnon KH, Elbashir SM, Shaw CA, Woods A, Fritch EJ, Martinez DR, Bock KW, Minai M, Nagata BM, Hutchinson GB, Bahl K, Garcia-Dominguez D, Ma L, Renzi I, Kong WP, Schmidt SD, Wang L, Zhang Y, Stevens LJ, Phung E, Chang LA, Loomis RJ, Altaras NE, Narayanan E, Metkar M, Presnyak V, Liu C, Louder MK, Shi W, Leung K, Yang ES, West A, Gully KL, Wang N, Wrapp D, Doria-Rose NA, Stewart-Jones G, Bennett H, Nason MC, Ruckwardt TJ, McLellan JS, Denison MR, Chappell JD, Moore IN, Morabito KM, Mascola JR, Baric RS, Carfi A, Graham BS. SARS-CoV-2 mRNA vaccine development enabled by prototype pathogen preparedness. BioRxiv. 2020, June 11. doi: 10.1101/2020.06.11.145920. PMID 32577634.

60. US National Library of Medicine. Clinical. Trials.gov, Phase I/II Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Canada. 2020 (May 21). NCT04398147.

61. US National Library of Medicine. Clinical. Trials.gov, Feasibility and Impact of Remote Oximetry in Patients Hospitalized With Covid-19NCT04336410.

62. Chinese Clinical Trail registry A randomized, double-blind, placebo parallel-controlled phase I/II clinical trial for inactivated Novel coronavirus Pneumonia vaccine (Vero cells); 2020-04-13.

63. US National Library of Medicine. Clinical. Trials.gov, Feasibility and Impact of Remote Oximetry in patients Hospitalized With Covid -19 NCT04383574.

64. US National Library of Medicine. Clinical. Trials.gov, Study to Describe the Safety, Tolerability, Immunogenicity, and Effcacy of RNA Vaccine Candidates Against COVID-19 in Healthy individuals NCT04368728.

65. US National Library of Medicine. Clinical. Trials.gov, Feasibility and Impact of Remote Oximetry in patients Hospitalized With Covid -19.

66. Nikhat S, Fazil M. Overview of Covid-19; its prevention and management in the light of Unani medicine. Sci Total Environ. 2020;728:138859. doi: 10.1016/j.scitotenv.2020.138859.

67. Ali I, Alharbi OML. COVID-19: Disease, management, treatment, and social impact. Sci Total Environ. 2020;728:138861. doi: 10.1016/j.scitotenv.2020.138861.

68. Yang Y, Islam MS, Wang J, Li Y, Chen X. Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): a review and perspective. Int J Biol Sci. 2020;16(10):1708-17. doi: 10.7150/ijbs.45538, PMID 32226288.

69. Wan Z, Zhang YN, He Z, Liu J, Lan K, Hu Y, Zhang C. A melting curve-based multiplex RT-qPCR assay for simultaneous detection of four human coronaviruses. Int J Mol Sci. 2016;17(11):1880. doi: 10.3390/ijms17111880, PMID 27886052.

70. Noh JY, Yoon SW, Kim DJ, Lee MS, Kim JH, Na W, Song D, Jeong DG, Kim HK. Simultaneous detection of severe acute respiratory syndrome, Middle East respiratory syndrome, and related bat coronaviruses by real-time reverse transcription PCR. Arch Virol. 2017;162(6):1617-23. doi: 10.1007/s00705-017-3281-9, PMID 28220326.

71. Lei J, Li J, Li X, Qi X. CT imaging of the 2019 novel coronavirus (2019-nCoV) pneumonia. Radiology. 2020;295(1):18-. doi: 10.1148/radiol.2020200236, PMID 32003646.

72. Morgello S. Coronaviruses and the central nervous system. J Neurovirol. 2020;26(4):459-73. doi: 10.1007/s13365-020-00868-7, PMID 32737861.

73. Loon SC, Teoh SCB. OonLEE, Se-ThoeSU, Ling AE, Leo YS, Leong HN. The severe acute respiratory 73. syndrome coronavirus in tears. British journal of ophthalmology. 2004:88(7):861-863. Doi: 10.1136/bjo.2003.035931